Improving Lives Through Nuclear Medicine™

About

Leadership Team

Sergio Calvo

President, Radiopharmaceuticals Division

Sergio Calvo was appointed as the President of the Radiopharmaceuticals Division of Jubilant Radiopharma in January 2020. He brings with him more than 20 years of experience in the global healthcare industry. Prior to joining the Jubilant team, Sergio was the General Manager of the Positron Emission Tomography segment of GE Healthcare, a global business that provides a broad range of technologies and services to the nuclear medicine and molecular imaging community. Prior to GE, he worked for Siemens Healthcare in a variety of positions of increasing responsibility in Brazil, Canada and the US. Sergio holds a graduate degree in Engineering.

Norman LaFrance

Chief Medical Officer and Senior VP, Medical & Regulatory Affairs

Dr. LaFrance, MD, ME, FACP, FACNP, joined Jubilant Radiopharmaceuticals in 2012 as Chief Medical Officer [CMO] and SVP, Medical & Regulatory Affairs. His broad experience spans over thirty-five years in the practice of medicine, pharmaceutical and healthcare industry, drug research & development and commercialization work with large pharmaceutical and specialty pharmaceutical, molecular imaging and therapeutic companies. Dr. LaFrance has had numerous submitted and approved NDA’s and many additional, successful phase 0-IV programs to his credit. Dr. LaFrance’s experience includes not only North America, but also Europe, Japan, Latin America, Asia and ROW. Important aspects of his responsibilities over the years included identifying, establishing and developing collaborations between industry, government and academia while supporting business development, marketing, and in-licensing objectives through a core of clinical, medical & regulatory affairs expertise. Prior to industry, Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the Departments of Medicine and Radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in Internal Medicine and Nuclear Medicine, maintains active Medical Licensure in the United States along with active, professional society membership.

James Kaufman

Vice-President, Devices

James Kaufman was appointed Vice-President, Marketing in August 2017. Jim joined the company in November 2016 bringing with him over 20 years of medical imaging experience with a strong proficiency in nuclear medicine and business development. Since joining, he has been instrumental in the successful launch of the RUBY-FILL® Rubidium (Rb-82) Generator and Ruby Rubidium Elution System. Prior to joining Jubilant Radiopharmaceuticals, he served as a Global Product Leader, Life Sciences-Core Imaging at GE Healthcare, specializing in the Cardiology product segment, as well as Neurology, Oncology and overall general nuclear imaging segments. Jim holds a Bachelor of Science in Business Administration and Marketing from Ashland University. He received his Nuclear Medicine Technology training at The Ohio State University.

Arpita Chatterjee

Vice-President, Finance

Ms. Arpita Chatterjee was appointed the Vice-President, Finance in April 2016. With over 22 years’ experience in finance and accounting, her main areas of expertise are financial reporting, management of global budgets, interpretation of financial data and staff management. More recently, she worked as Global Director, Finance and Administration for MIP Inc – Montreal. Arpita is responsible for the JHS and JDI finance departments. Arpita holds a Bachelor of Commerce and is a member of the CPA.

Bill Riddoch

Sr. Director, Research and Development

Dr. Riddoch, B.Sc., Ph.D. has headed the Research and Development group since November 2014 and is responsible for overseeing Jubilant Radiopharmaceuticals’s development pipeline as well as the radiation safety program. Prior to this Dr. Riddoch served in several different positions: Director of Manufacturing Operations (2012-2014), Senior Manager of Research and Development (2011 – 2012) and Senior Scientist (2001 – 2011). Over his career he has been responsible for the development, validation and trouble shooting of many of the products which make up the company’s current Product Portfolio. Dr. Riddoch is an experienced radiochemist, whose research has focused on technetium chelation chemistry and radiohalogen chemistry. He holds an honours B.Sc. and a Ph.D. in Chemistry from McMaster University.

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.